Bristol-Myers Squibb Company

Open: 48.82 Close: 48.89 Change: 0.07

We programmed an AI to read Internet. This is what it found out about Bristol-Myers Squibb Company Company Inc.

Are looking for the most relevant information about Bristol-Myers Squibb Company? Investor spend a lot of time searching for information to make investment decisions in Bristol-Myers Squibb Company. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Bristol-Myers Squibb Company are: stock, Bristol, Myers, Squibb, fall, Monday, investor, and the most common words in the summary are: squibb, myers, bristol, company, bristolmyers, stock, market, . One of the sentences in the summary was: If certain milestones are met, VantAI could be …

Concept Map

Semantic Network

Stock Summary

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology,.

Today's Summary

Bristol Myers Squibb stock is falling on Monday as investors in BMY shares react to two updates weighing on the companys stock. If certain milestones are met, VantAI could be in line to receive up to $674m from BMS.

Today's News

Bristol Myers Squibb stock is falling on Monday as investors in BMY shares react to two updates weighing on the companys stock. If certain milestones are met, VantAI could be in line to receive up to $674m from BMS.

Stock Profile

"Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York."

Keywords

How much time have you spent trying to decide whether investing in Bristol-Myers Squibb Company? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Bristol-Myers Squibb Company are: stock, Bristol, Myers, Squibb, fall, Monday, investor, and the most common words in the summary are: squibb, myers, bristol, company, bristolmyers, stock, market, . One of the sentences in the summary was: If certain milestones are met, VantAI could be in line to receive up to $674m from BMS.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #squibb #myers #bristol #company #bristolmyers #stock #market.